Clinical Trials Browser

Phase 1/2 × cabiralizumab × 90 days × Clear all

NCT04331067 2026-05-06

Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer

Phase 1/2 Active not recruiting

15 enrolled 12 charts

Triple Negative Breast Neoplasms